Oculomotor and Spatial Cognition Deficits in Schizophrenia
This study has been terminated.
(Study was terminated due to low accrual.)
Sponsor:
University of Illinois
Collaborator:
Information provided by (Responsible Party):
Jeffrey R. Bishop, University of Illinois
ClinicalTrials.gov Identifier:
NCT00931996
First received: June 25, 2009
Last updated: January 23, 2013
Last verified: January 2013
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
DESCRIPTION: (Verbatim from the Applicant's Abstract) Abnormalities of eye movement control and spatial cognition are well-established deficits in schizophrenia. However, the regional disturbances in brain function causing these deficits are not yet known. This application proposes a series of integrated behavioral studies designed to identify causes of deficits in schizophrenia.
| Condition | Intervention |
|---|---|
|
Schizophrenia |
Drug: Antipsychotic |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Basic Science |
| Official Title: | Clinical and Computational Studies of Dopamine Function in Schizophrenia |
Resource links provided by NLM:
Further study details as provided by University of Illinois:
Primary Outcome Measures:
- Positive and Negative Syndrome Scale (PANSS) Score Change From Baseline. [ Time Frame: Baseline and 6 weeks ] [ Designated as safety issue: No ]Positive and Negative Syndrome Scale (PANSS) Total Score. 1 to 7 on 30 different symptoms based on the interview as well as reports of family members or primary care hospital workers. PANSS Total score minimum = 30, maximum = 210 Higher scores represent more severe symptoms. A positive change score (baseline-6 weeks) indicates an improvement in symptoms.
| Enrollment: | 12 |
| Study Start Date: | June 2009 |
| Study Completion Date: | November 2011 |
| Primary Completion Date: | November 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Antipsychotic
Antipsychotic
|
Drug: Antipsychotic
Risperidone is the first line antipsychotic followed by others per clinician choice. Flexible dosing QD x 4-6 weeks.
|
Detailed Description:
We will be assessing clinical symptoms and cognition before and after treatment.
Eligibility| Ages Eligible for Study: | 15 Years to 64 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Inclusion Criteria: Inclusion criteria for this study are (1) able and willing to give written informed consent; (2) no contraindications to MRI (cardiac pacemaker, aneurysm clip, cochlear implants, IUD, shrapnel, history of metal fragments in eyes, neurostimulators or other metal devices, weight of 250lbs or more, claustrophobia) and (3) medically stable. Sedation will not be used for MRI studies because cooperation is essential.
Exclusion Criteria:
- Any subject is excluded from the imaging studies if they have any contraindications to MRI such as cardiac pacemaker, aneurysm clip, cochlear implants, pregnancy in the later stages (because of body size and limited comfort for MRI studies), IUD, shrapnel, history of metal fragments in eyes, neurostimulators, weight of 250 lbs. or more, or claustrophobia. Individuals with mental retardation, neurologic disease or significant medical illness that might effect neuronal or vascular physiology will not be recruited.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00931996
Locations
| United States, Illinois | |
| UIC Center for Cognitive Medicine | |
| Chicago, Illinois, United States, 60612 | |
Sponsors and Collaborators
University of Illinois
Investigators
| Principal Investigator: | John A Sweeney, PhD | UIC/UTSW |
More Information
No publications provided
| Responsible Party: | Jeffrey R. Bishop, Assistant Professor, University of Illinois |
| ClinicalTrials.gov Identifier: | NCT00931996 History of Changes |
| Other Study ID Numbers: | 2001-0522, R01MH062134, R01MH080066 |
| Study First Received: | June 25, 2009 |
| Results First Received: | November 8, 2011 |
| Last Updated: | January 23, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Illinois:
|
schizophrenia antipsychotic risperidone |
Additional relevant MeSH terms:
|
Schizophrenia Schizophrenia and Disorders with Psychotic Features Mental Disorders Antipsychotic Agents Tranquilizing Agents Central Nervous System Depressants |
Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Psychotropic Drugs |
ClinicalTrials.gov processed this record on May 23, 2013